JonesTrading analyst Debanjana Chatterjee has maintained their neutral stance on CLSD stock, giving a Hold rating on July 29.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Debanjana Chatterjee has given his Hold rating due to a combination of factors surrounding Clearside Biomedical’s current financial and strategic situation. The company concluded the second quarter of 2025 with a cash reserve of $9.4 million, which is set to decrease further due to anticipated severance and termination costs in the third quarter.
Additionally, Clearside Biomedical is in the process of exploring strategic alternatives, with all research and development activities currently on hold until more capital becomes available. While there is potential interest in the company’s platform and its CLS-AX product, the outcome and timing of any strategic transaction remain uncertain. Given these circumstances, the decision to maintain a Hold rating reflects the unclear future path for the company.
In another report released on July 29, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $0.50 price target.